SML2223

WAY-267464 dihydrochloride

Name: WAY-267464 dihydrochloride
Brand: SIGMA
Price: 785 PLN

≥98% (HPLC)

Synonim(y):

4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide dihydrochloride, N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamide dihydrochloride, WAY 267,464 dihydrochloride, WAY 267464 dihydrochloride, WAY-267,464 dihydrochloride, WAY267464 dihydrochloride

Slide 1 of 1

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

5 MG

785,00 zł

25 MG

2560,00 zł

785,00 zł

Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):

C₃₂H₃₅N₇O₄ · 2HCl

Numer CAS:

1432043-31-6

Masa cząsteczkowa:

654.59

UNSPSC Code:

12352200

NACRES:

NA.77

MDL number:

MFCD23135228

Assay:

≥98% (HPLC)

Form:

powder

Storage condition:

desiccated

Kluczowe dokumenty

Wyświetl całą dokumentację

Przejdź do

Pomoc techniczna

Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.

Pozwól nam pomóc

InChI

1S/C32H35N7O4.2ClH/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22;;/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43);2*1H

SMILES string

O=C(NCC1=CC=C(C=C1C)C(N2CC3=C(NC4=CC=CC=C24)N(N=C3)C)=O)N5CCN(CC5)CC6=CC(O)=CC(O)=C6

InChI key

OTFWXMFLPMUDFP-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H₂O: 2 mg/mL, clear

storage temp.

2-8°C

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja	SML2417	SML2698	SML0276
Sigma-Aldrich SML2223 WAY-267464 dihydrochloride	Sigma-Aldrich SML2417 ORG 25543 Hydrochloride	Sigma-Aldrich SML2698 EVT-101 dihyrochloride	Sigma-Aldrich SML0276 BD 1063 dihydrochloride
form powder	form powder	form powder	form powder
assay ≥98% (HPLC)	assay ≥95% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
storage temp. 2-8°C	storage temp. room temp	storage temp. 2-8°C	storage temp. room temp
storage condition desiccated	storage condition desiccated	storage condition desiccated	storage condition desiccated
solubility H₂O: 2 mg/mL, clear	solubility DMSO: 2 mg/mL, clear	solubility H₂O: 2 mg/mL, clear	solubility H₂O: >15 mg/mL
color white to beige	color white to beige	color white to beige	color white to beige

Biochem/physiol Actions

Non-peptide oxytocin receptor (OTR) agonist and vasopressin V1a receptor (V1aR) antagonist.

WAY-267464 is a non-peptide drug with a novel mechanism of action (MOA) to treat psychosis and schizophrenia.[1]

WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist (EC50 = 61-881 nM; Ki = 58-978 nM) that, unlike oxytocin (OT), displays antagonist instead of agonist activity toward vasopressin V1a receptor/V1aR (IC50 = 613 nM; Ki = 27-113 nM). WAY-267464 exhibits OT-like anxiolytic effects in assays measuring both behavioral (33% increase in punished crossing by 10 mg/mL ip or 10 μg/mouse icv in four-plate tests; 75% increased open quadrants stay by 3 μg/mouse icv in elevated zero maze) and autonomic (47% higher stress-induced hyperthermia by 10 μg/mouse icv) parameters of the anxiety response. Similar to the antipsychotic-like effects reported for OT, WAY-267464 also reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine. Unlike OT, WAY-267464 does not affect immobility in mouse tail suspension test.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Wyszukaj dokument COA

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.

Robert H Ring et al.

Neuropharmacology, 58(1), 69-77 (2009-07-21)

The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression. The utility of synthetic

Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.

William T Jorgensen et al.

European journal of medicinal chemistry, 108, 730-740 (2016-01-08)

A previously identified, non-peptidic oxytocin (OT) receptor agonist WAY-267,464 (1) and nine novel derivatives (3, 4a-7a, 4b-7b) were synthesised and evaluated in vitro with the aim of systematically exploring hydrogen bonding interactions and ligand flexibility. All analogues were subjected to competition

Oxytocin signaling in basolateral and central amygdala nuclei differentially regulates the acquisition, expression, and extinction of context-conditioned fear in rats.

Emma J Campbell-Smith et al.

Learning & memory (Cold Spring Harbor, N.Y.), 22(5), 247-257 (2015-04-17)

The present study investigated how oxytocin (OT) signaling in the central (CeA) and basolateral (BLA) amygdala affects acquisition, expression, and extinction of context-conditioned fear (freezing) in rats. In the first set of experiments, acquisition of fear to a shocked context

Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats.

C Hicks et al.

British journal of pharmacology, 171(11), 2868-2887 (2014-03-20)

There is current interest in oxytocin (OT) as a possible therapeutic in psychiatric disorders. However, the usefulness of OT may be constrained by peripheral autonomic effects, which may involve an action at both OT and vasopressin V1A receptors. Here, we

Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors.

William T Jorgensen et al.

European journal of medicinal chemistry, 143, 1644-1656 (2017-11-12)

WAY-267,464 (1) and twelve conformationally rigid analogues (3a-f-4a-f) were synthesised, characterised and evaluated in cellular assays with the aim of systematically exploring interactions with the oxytocin receptor (OTR). Each analogue was evaluated in radioligand binding displacement assays at both human

Wyświetl wszystkie powiązane dokumenty

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej

WAY-267464 dihydrochloride